sleep

Cognitive behavioral therapy appears more effective than sleep medication for treating insomnia (press release)

Tuesday, August 29, 2006 by: NaturalNews
Tags: health news, Natural News, nutrition

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
Biologist explains how marijuana causes tumor cells to commit suicide
Companies begin planting microchips under employees' skin
NJ cops bust teenagers shoveling snow without a permit
Chemotherapy kills cancer patients faster than no treatment at all
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
FDA targets Dr. Bronner's Magic Soaps for sharing health benefits of coconut oil
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
Orthorexia Nervosa - New mental disorder aimed at people who insist on eating a clean diet
Whooping cough outbreak at Massachusetts high school affected only vaccinated students
Inuit Elders tell NASA Earth Axis Shifted
Vaccine flu shots still contain 25 micrograms mercury - 100 times the concentration of 'mercury-loaded' fish
Measles outbreak likely caused by vaccinated children, science shows
Baby formula is loaded with GMOs - Avoid these brands
Extreme trauma from male circumcision causes damage to areas of brain
Terminal stage IV lung cancer patient miraculously cured by cannabis oil
Costco stops selling antibiotic laden chicken in response to consumer demand
FDA cracks down Walmart, GNC, other companies selling supplements that do not contain the herbs on the label
McDonald's french fries found to contain Silly Putty ingredient and petroleum chemical

Delicious
Patients with insomnia who implemented cognitive behavioral therapy interventions such as relaxation techniques had greater improvement in their sleep than patients who received the sleep medication zopiclone, according to a study in the June 28 issue of JAMA.

Insomnia is usually defined as subjective complaints of poor sleep accompanied by impairment in daytime function. It is common in people aged older than 55 years (9 percent-25 percent are affected) and is associated with reduced quality of life, depression, and more physician visits. Despite these links to individuals' lives and societal costs, most people with chronic insomnia–up to 85 percent–remain untreated, according to background information in the article. Two-thirds of individuals with insomnia report having poor knowledge of available treatment options, and as many as one fifth resort to either untested over-the-counter medications or alcohol in attempts to improve their condition. Among primary care physicians, the treatment of choice for insomnia has commonly been prescription medication. Cognitive behavioral therapy (CBT) is the most widely used psychological intervention for insomnia. No studies have compared the newer non-benzodiazepine sleep medications with nonpharmacological treatments.

Borge Sivertsen, Psy.D., of the University of Bergen, Norway, and colleagues conducted a randomized controlled trial between January 2004 and December 2005 to compare the short- and long-term clinical efficacy of CBT and the non-benzodiazepine sleep medication zopiclone. The trial included 46 adults (average age 60.8 years; 22 women) with chronic primary insomnia. The participants received either the CBT intervention (information on sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and progressive relaxation technique; n = 18), sleep medication (7.5 mg zopiclone each night; n = 16), or placebo medication (n = 12). All treatment duration was 6 weeks, and the 2 active treatments were followed up at 6 months. Clinical polysomnographic data and sleep diaries were used to determine total wake time, total sleep time, sleep efficiency, and slow-wave sleep (only assessed using polysomnography [PSG; monitoring of physiological activity during sleep]).

Using PSG testing, the total time spent awake during the night for the CBT group improved significantly more than both the placebo group at 6 weeks and the zopiclone group at both 6 weeks and 6 months. The zopiclone group did not differ significantly from the placebo group. Total wake time at 6 weeks was reduced 52 percent in the CBT group compared with 4 percent and 16 percent in the zopiclone and placebo groups on PSG testing, respectively. On average, participants receiving CBT improved their PSG-registered sleep efficiency by 9 percent at posttreatment, compared with a decline of 1 percent in the zopiclone group, a difference that the authors stated was both statistically and clinically significant.

Total sleep time measured using both PSG and sleep diary increased significantly in the CBT group at 6 months compared with 6 weeks. The zopiclone group showed no significant change at 6 months on PSG, maintaining improvements seen at 6 weeks. Comparing the 2 active treatment conditions, total wake time, sleep efficiency, and slow-wave sleep were all significantly better in the CBT group than in the zopiclone group as assessed using PSG; total sleep time was not significantly different .

"… the present findings have important implications for the clinical management of chronic primary insomnia in older adults. Given the increasing amount of evidence of the lasting clinical effects of CBT and lack of evidence of long-term efficacy of hypnotics, clinicians should consider prescribing hypnotics only for acute insomnia. At present, CBT-based interventions for insomnia are not widely available in clinical practice, and future research should focus on implementing low-threshold treatment options for insomnia in primary care settings. As recently demonstrated by Bastien et al, telephone consultations and CBT-based group therapy for younger patients with insomnia produced equally significant improvements as individual therapy sessions. In another study, CBT delivered via the Internet in a self-help format showed significant improvements in individuals with chronic insomnia," the authors write. "Finally, future research should seek to identify which single factors in the CBT regimen produce the best results and to what extent booster sessions at 1 to 2 years after initial treatment may be necessary to maintain improvements."

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.